Clinical trialPhase 2Withdrawn
BKM120 in Cancers With PIK3CA Activating Mutations
An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations
- Outcome
- Stopped earlyThe study has been closed due to lack of accrual (Enrollment)
- Phase
- Phase 2
- Status
- Withdrawn
- Study type
- Interventional
- Start
- January 2012
- Expected end
- August 2013
- Enrollment
- 0 participants
- Sites
- 0
- Primary outcomes
- Response Rate
- Sponsor
- Other
- Results posted
- No
- Last update
- 17 September 2015
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
In people whos cancers have a PIK3CA mutation, this trial will be evaluating the drug BKM120 as a possible treatment. BKM120 works by blocking the phosphatidylinositol-3-kinase (PI3K)pathway, thereby inhibiting tumor growth and survival. The purpose of this study is to learn if the study drug BKM120 can shrink or slow the growth of your tumor. The safety of BKM120 will also be studied. Your physical state, symptoms, change in the size of your tumor, and laboratory findings obtained while you are on study will help the research team decide if BKM120 is safe and effective in patients with advanced cancers.
Detailed description public domain (ClinicalTrials.gov)
Subjects enrolled in this study will receive BKM120 once daily, orally, in cycles of 28 days. During Cycles 1 and 2, the following tests and procedures will be done on days 1 and 15: * physical exam * performance status * blood tests * pregnancy test (if applicable) * neuropsychiatric assessments Starting at Cycle 2 and then every other cycle thereafter (approximately every 8 weeks) tumor assessment will be performed by CT/MRI or PET scan. A chest x-ray will also be performed every 8 weeks. Beginning with Cycle 3, the following tests/procedures will be performed on Day 1 of each cycle: * physical exam * performance status * blood tests * neuropsychiatric assessments